glp-1 options for type 2 diabetes and obesity 2025 Chart: 1 in 8 Americans Now Use Drugs Weight Loss GLP-1 agonists and changes in

Head discomfort is sometimes reported

To ensure that those most in need receive treatment even if cost constraints limit broader access, coverage should be allocated based on criteria such as severity of obesity, comorbidities, and age

Lillys phase 2 retatrutide trial achieved up to 17.5% mean weight reduction at 24 weeks

At an April 18 session at the annual American Association for Cancer Research meeting, scientists offered an update on the field and weighed the evidence for any cancer prevention powers

Mental tools to cope with stress and boost resilience are invaluable when stopping GLP-1s

If used for diabetes care, consult with an endocrinologist to possibly bridge therapy to minimize the risk of hypoglycemia